Stephen Thomas Keir

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. doi request reprint Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program
    Stephen T Keir
    Duke University Medical Center, Durham, North Carolina, USA
    Pediatr Blood Cancer 60:783-90. 2013
  2. doi request reprint Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program
    Stephen T Keir
    Duke University Medical Center, Durham, North Carolina, USA
    Pediatr Blood Cancer 59:586-8. 2012
  3. ncbi request reprint Screening for distress in patients with brain cancer using the NCCN's rapid screening measure
    Stephen T Keir
    The Tug McGraw Research Center, The Preston Robert Tisch Brain Tumor Center at Duke, 3624 DUMC, Durham, NC 27710, USA
    Psychooncology 17:621-5. 2008
  4. ncbi request reprint Levels of stress and intervention preferences of caregivers of brain tumor patients
    Stephen T Keir
    Tug McGraw Center for QOL Supportive Care Research, The Preston Robert Tisch Brain Tumor Center, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Nurs 30:E33-9. 2007
  5. doi request reprint Distress persists in long-term brain tumor survivors with glioblastoma multiforme
    Stephen T Keir
    Surgery Department, Tug McGraw Research Center, Preston Robert Tisch Brain Tumor Center at Duke, Durham, NC, USA
    J Cancer Surviv 2:269-74. 2008
  6. ncbi request reprint Differential levels of stress in caregivers of brain tumor patients--observations from a pilot study
    Stephen T Keir
    The Tug McGraw Center for Quality of Life Supportive Care Research, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, DUMC Box 3624, Durham, NC, USA
    Support Care Cancer 14:1258-61. 2006
  7. ncbi request reprint Stress and intervention preferences of patients with brain tumors
    Stephen T Keir
    The Tug McGraw Center for Quality of Life Supportive Care Research, The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, P O Box 3624, Durham, NC 27710, USA
    Support Care Cancer 14:1213-9. 2006
  8. doi request reprint Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program
    Stephen T Keir
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA
    Pediatr Blood Cancer 55:1126-33. 2010
  9. doi request reprint Effect of massage therapy on stress levels and quality of life in brain tumor patients--observations from a pilot study
    Stephen Thomas Keir
    Duke University Medical Center, The Preston Robert Tisch Brain Tumor Center at Duke, DUMC Box 3624, Durham, NC 27710, USA
    Support Care Cancer 19:711-5. 2011
  10. pmc Cellular redox modulator, ortho Mn(III) meso-tetrakis(N-n-hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP(5+) in the treatment of brain tumors
    Stephen T Keir
    Preston Robert Tisch Brain Tumor Center at Duke, Duke University, Durham, NC 27710, USA
    Anticancer Agents Med Chem 11:202-12. 2011

Detail Information

Publications37

  1. doi request reprint Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program
    Stephen T Keir
    Duke University Medical Center, Durham, North Carolina, USA
    Pediatr Blood Cancer 60:783-90. 2013
    ..However, preclinical data have suggested a broader application for treatment of childhood cancer. Temozolomide was tested against the PPTP solid tumor and ALL models...
  2. doi request reprint Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program
    Stephen T Keir
    Duke University Medical Center, Durham, North Carolina, USA
    Pediatr Blood Cancer 59:586-8. 2012
    ..Though well tolerated, pazopanib showed limited activity against the sarcoma models evaluated, with the best tumor responses being growth delay...
  3. ncbi request reprint Screening for distress in patients with brain cancer using the NCCN's rapid screening measure
    Stephen T Keir
    The Tug McGraw Research Center, The Preston Robert Tisch Brain Tumor Center at Duke, 3624 DUMC, Durham, NC 27710, USA
    Psychooncology 17:621-5. 2008
    ..Using the National Comprehensive Cancer Network's Distress Thermometer, we evaluated the extent and sources of distress within a population of patients with brain cancer...
  4. ncbi request reprint Levels of stress and intervention preferences of caregivers of brain tumor patients
    Stephen T Keir
    Tug McGraw Center for QOL Supportive Care Research, The Preston Robert Tisch Brain Tumor Center, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Nurs 30:E33-9. 2007
    ..These data provide further evidence that caregivers experience elevated levels of stress and are willing to learn more about and participate in programs to reduce stress...
  5. doi request reprint Distress persists in long-term brain tumor survivors with glioblastoma multiforme
    Stephen T Keir
    Surgery Department, Tug McGraw Research Center, Preston Robert Tisch Brain Tumor Center at Duke, Durham, NC, USA
    J Cancer Surviv 2:269-74. 2008
    ..However, little is known about the psychological correlates of this disease. To address this issue we investigated distress and its sources in long-term survivors (LTS) of this disease...
  6. ncbi request reprint Differential levels of stress in caregivers of brain tumor patients--observations from a pilot study
    Stephen T Keir
    The Tug McGraw Center for Quality of Life Supportive Care Research, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, DUMC Box 3624, Durham, NC, USA
    Support Care Cancer 14:1258-61. 2006
    ..Using pilot data, we sought to determine which caregivers are at risk for experiencing elevated levels of stress based on caregiver-demographic and patient-medical information...
  7. ncbi request reprint Stress and intervention preferences of patients with brain tumors
    Stephen T Keir
    The Tug McGraw Center for Quality of Life Supportive Care Research, The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, P O Box 3624, Durham, NC 27710, USA
    Support Care Cancer 14:1213-9. 2006
    ..To design effective stress reduction interventions, it is essential to have an understanding of the beliefs, past experiences, and preferences concerning stress reduction techniques and programs among patients with BTs...
  8. doi request reprint Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program
    Stephen T Keir
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA
    Pediatr Blood Cancer 55:1126-33. 2010
    ..g., VEGF receptors, PDGFR, FLT3, RET, BRAF, KIT) and is approved by FDA for treatment of two adult cancers. The activity of sorafenib was evaluated against the PPTP's in vitro and in vivo panels...
  9. doi request reprint Effect of massage therapy on stress levels and quality of life in brain tumor patients--observations from a pilot study
    Stephen Thomas Keir
    Duke University Medical Center, The Preston Robert Tisch Brain Tumor Center at Duke, DUMC Box 3624, Durham, NC 27710, USA
    Support Care Cancer 19:711-5. 2011
    ..The purpose of this pilot study was to obtain a preliminary assessment of the efficacy of massage therapy on patient reported psychological outcomes and QoL...
  10. pmc Cellular redox modulator, ortho Mn(III) meso-tetrakis(N-n-hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP(5+) in the treatment of brain tumors
    Stephen T Keir
    Preston Robert Tisch Brain Tumor Center at Duke, Duke University, Durham, NC 27710, USA
    Anticancer Agents Med Chem 11:202-12. 2011
    ..Our findings suggest that the use of Mn porphyrin-based SOD mimics, and in particular lipophilic analogues such as MnTnHex-2-PyP(5+), is a promising approach for brain tumor therapy...
  11. ncbi request reprint Stress and long-term survivors of brain cancer
    Stephen T Keir
    The Tug McGraw Research Center, The Preston Robert Tisch Brain Tumor Center, Duke Surgery Department, Division of Neuro Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Support Care Cancer 15:1423-8. 2007
    ..As a result, health care providers are faced with new challenges to address the need for psychosocial support in this population...
  12. ncbi request reprint The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion
    Anita B Hjelmeland
    Department of Surgery, Duke University Medical Center, P O Box 2900, Durham, NC 27710, USA
    Mol Cancer Ther 6:2449-57. 2007
    ..These data suggest that the combination of LBT613 and RAD001 reduces glioma cell proliferation and invasion and support examination of the combination of RAF and TOR inhibitors for the treatment of human glioblastoma patients...
  13. ncbi request reprint Using the theory of planned behavior to understand the determinants of exercise intention in patients diagnosed with primary brain cancer
    Lee W Jones
    Duke University Medical Center, Durham, NC 27710, USA
    Psychooncology 16:232-40. 2007
    ..Information gained from this study suggests that the TPB is a useful framework to design and implement theoretically based interventions to promote exercise in primary brain cancer patients...
  14. pmc Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer
    Lee W Jones
    Duke Univ Medical Center, Durham, NC 27710, USA
    J Appl Physiol 108:343-8. 2010
    ..Such findings may have important implications for inhibiting tumor metastasis and improving the efficacy of conventional cancer therapies...
  15. ncbi request reprint Patterns of exercise across the cancer trajectory in brain tumor patients
    Lee W Jones
    Department of Surgery Neuro Oncology, Duke University Medical Center, Durham, North Carolina 27705, USA
    Cancer 106:2224-32. 2006
    ..Given the limited evidence, the authors conducted a survey to examine the exercise patterns of brain tumor patients across the cancer trajectory...
  16. pmc Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas
    Chien Tsun Kuan
    Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC 27710, USA
    Int J Cancer 129:111-21. 2011
    ..These GPNMB-specific scFv antibodies and immunotoxins hold promise as reagents in targeted therapy for HGGs and other GPNMB-expressing malignancies...
  17. ncbi request reprint A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth
    Qing Shi
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Mol Carcinog 46:488-96. 2007
    ..TAE226 also decreased glioma cell adhesion, migration, and invasion through an artificial extracellular matrix. Together, these data demonstrate the potential benefit of TAE226 for glioma therapy...
  18. ncbi request reprint ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors
    Jeremy N Rich
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 11:8145-57. 2005
    ..Current nonspecific therapies frequently have poor efficacy in many of these tumor types, so there is a pressing need for the development of novel targeted therapies...
  19. ncbi request reprint Exercise interest and preferences among patients diagnosed with primary brain cancer
    Lee W Jones
    Duke University Medical Center, Durham, NC 27710, USA
    Support Care Cancer 15:47-55. 2007
    ..Secondary aims were to examine potential differences in participant's interest and preferences by exercise behavior and select demographic/medical variables...
  20. ncbi request reprint Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition
    Ranjit K Goudar
    Department of Pathology, Duke University Medical Center, P O Box 2900, Durham, NC 27710, USA
    Mol Cancer Ther 4:101-12. 2005
    ..These studies suggest that simultaneous inhibition of growth factor receptor and mTOR pathways offer increased benefit in glioma therapy...
  21. ncbi request reprint Program preferences to reduce stress in caregivers of patients with brain tumors
    Jonas J Swartz
    Preston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA
    Clin J Oncol Nurs 11:723-7. 2007
    ..This information provides valuable insight for researchers designing studies to address the experiences of stressed caregivers...
  22. pmc Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program
    Stephen T Keir
    Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina 27710, USA
    Pediatr Blood Cancer 51:439-41. 2008
    ..VNP4010M antitumor activity was observed only in the absence of MGMT expression, with resistance to VNP4010M seen even with low MGMT expression...
  23. ncbi request reprint AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma
    Sith Sathornsumetee
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Res 66:8722-30. 2006
    ....
  24. pmc HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea
    Genglin Jin
    Department of Pathology, Pediatric Brain Tumor Foundation Institute and Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, North Carolina 27710, USA
    Neuro Oncol 12:956-66. 2010
    ..In summary, HDMX exhibits bona fide oncogenic properties and offers a promising molecular target for GBM therapeutic intervention...
  25. ncbi request reprint Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft
    C Lynn Cheng
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Mol Cancer Ther 4:1364-8. 2005
    ..9 and 45.7 days, respectively. These results suggest that inhibition of PARP may increase the efficacy of temozolomide in the treatment of malignant gliomas, particularly in tumors deficient in DNA mismatch repair...
  26. ncbi request reprint The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors
    Henry S Friedman
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 97:2359-62. 2003
    ..Studies currently are addressing the role of O(6)-alkylguanine-DNA alkyltransferase (AGT) in reducing the benefits of combining CPT-11 with temozolomide and the potential therapeutic gain from utilizing an inhibitor of AGT...
  27. ncbi request reprint Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program
    Peter J Houghton
    St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Pediatr Blood Cancer 50:37-45. 2008
    ..The purpose of the current study was to evaluate the antitumor activity of bortezomib against the in vitro and in vivo childhood cancer preclinical models of the Pediatric Preclinical Testing Program (PPTP)...
  28. ncbi request reprint Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program
    John M Maris
    Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine and Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania, USA
    Pediatr Blood Cancer 50:581-7. 2008
    ..This study was designed to screen for antitumor activity of AZD2171 against the in vitro and in vivo childhood cancer preclinical models of the Pediatric Preclinical Testing Program (PPTP)...
  29. pmc Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice
    Michael A Badruddoja
    Center for Neurosciences, University of Arizona, Tucson, AZ 85721, USA
    Neuro Oncol 9:240-4. 2007
    ..001), with one toxic death. These findings suggest that VNP40101M is active in the treatment of a wide range of human central nervous system tumors and warrants translation to the clinic...
  30. ncbi request reprint Initial testing of cisplatin by the pediatric preclinical testing program
    Mimi Tajbakhsh
    Children s Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia
    Pediatr Blood Cancer 50:992-1000. 2008
    ..Cisplatin is one of the most widely used drugs for the treatment of solid tumors in adults and children. Here, we report the activity of cisplatin against the PPTP panels of childhood cancer xenografts...
  31. ncbi request reprint Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program
    Peter J Houghton
    St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Pediatr Blood Cancer 50:799-805. 2008
    ..Here we report the activity of rapamycin against the in vitro and in vivo panels of the Pediatric Preclinical Testing Program (PPTP)...
  32. ncbi request reprint The pediatric preclinical testing program: description of models and early testing results
    Peter J Houghton
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Pediatr Blood Cancer 49:928-40. 2007
    ..Here, we describe the characteristics of the in vivo tumor panels and report results for the in vivo evaluation of two standard agents, vincristine and cyclophosphamide...
  33. ncbi request reprint Initial testing of dasatinib by the pediatric preclinical testing program
    E Anders Kolb
    The Children s Hospital at Montefiore, Bronx, New York, USA
    Pediatr Blood Cancer 50:1198-206. 2008
    ..Dasatinib, a dual inhibitor of the src and abl tyrosine kinases, was recently approved by the Federal Drug Administration for the treatment of imatinib mesylate-resistant chronic myeloid leukemia...
  34. ncbi request reprint Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program
    Richard Lock
    Children s Cancer Institute Australia for Medical Research, Randwick, NSW, Australia
    Pediatr Blood Cancer 50:1181-9. 2008
    ....
  35. doi request reprint Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program
    E Anders Kolb
    Albert Einstein College of Medicine, The Children s Hospital at Montefiore, Bronx, New York, USA
    Pediatr Blood Cancer 50:1190-7. 2008
    ..The activity of SCH 717454 was evaluated against the in vitro and in vivo panels of the Pediatric Preclinical Testing Program (PPTP)...
  36. doi request reprint Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program
    Malcolm A Smith
    Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland
    Pediatr Blood Cancer 51:34-41. 2008
    ..Alvespimycin (17-DMAG, KOS-1022), a potent small-molecule inhibitor of the protein chaperone Hsp90, is being developed as an anticancer agent because of the multiple Hsp90 client proteins involved in cancer cell growth and survival...
  37. doi request reprint Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program
    John M Maris
    Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine and Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania, USA
    Pediatr Blood Cancer 51:42-8. 2008
    ..Sunitinib is an orally bioavailable, multi-targeted tyrosine kinase inhibitor with selectivity for PDGF receptors, VEGF receptors, FLT3, and KIT...